Immuron

Australia - Blackburn NorthBiotechnology

Focus: Immuron is an Australian biotechnology company specializing in oral immunotherapy and supplements, operating at a small scale from Blackburn North. Limited public data suggests a niche, early-stage focus.

Infectious Diseases Metabolic Diseases

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Open Jobs

About Immuron

AI assessmentNot Hiring

No open roles listed right now. Follow Immuron to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IMM-529

Clostridium Difficile Infection

Phase 1/2

Clinical Trials (1)

NCT03065374Treatment for Clostridium-difficile Infection With IMM529

Phase 1/2

Help build intelligence for Immuron

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in the emerging oral immunotherapy space, a differentiated modality with less competition than monoclonal antibodies
Early-stage company offers potential equity upside and broader responsibility scope for individual contributors
Location in Australia may offer lifestyle benefits and lower cost of living relative to major pharma hubs

Watch Out For

No active job openings currently listed, suggesting minimal hiring or uncertain headcount needs
Extremely limited public data on financials, funding, or clinical pipeline reduces ability to assess company stability or near-term prospects
Single Phase 2 program with no Phase 3 catalyst on horizon raises questions about clinical validation and revenue timeline

Generated by Claude from Immuron's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IMM 124-E

Nonalcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT01466894Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Phase 2

IMM-124E

Non-alcoholic Steatohepatitis (NASH)

Phase 2

Clinical Trials (1)

NCT02316717A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Phase 2